GT Biopharma Inc

-0.13 (-6.40%)

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Published: 08/30/2022 22:20 GMT
GT Biopharma Inc (GTBP) - Gt Biopharma Affirms Manufacturing Timeline for Lead Investigational Asset Gtb-3650.
Gt Biopharma Inc - Gtb-3650's Ind Application With FDA Expected by End of Q1 of 2023.
Gt Biopharma Inc - Entering Into a Settlement and Investment Agreement With Its Contract Manufacturing Partner Cytovance Biologics.
Gt Biopharma Inc - Expects to File Its Ind Application With FDA for Its Gtb-5550 Product No Later Than June 30, 2023.